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ABSTRACT 
Meagan Elizabeth Buchanan: Interactions of Fentanyl with gp120 in the Central Nervous 
System 
(Under the direction of Dr. Jason Paris) 
            The Human Immunodeficiency Virus (HIV) has affected more than 75 million 
individuals worldwide. HIV not only affects the peripheral system through the targeting 
of T cells, but also causes adverse effects in the central nervous system. Individuals 
suffering from HIV often experience neuropathic pain and are prescribed opioids to 
combat the chronic pain. Along with the increase of opioids prescribed to HIV patients, 
the number of deaths related to the synthetic opioid, fentanyl, has increased drastically. 
Drug abuse and HIV are interlinked epidemics; individuals who are HIV positive and 
referred to as “NeuroAIDS.”  The HIV envelope protein, gp120, has been shown to have 
a wide variety of neurotoxic effects on the CNS through increasing cell death of 
astrocytes through stress-mediated apoptosis, increasing the permeability of the Blood 
Brain Barrier (BBB), increasing the expression of proinflammatory cytokines and 
chemokines, and altering and damaging mitochondria. The purpose of these 
experiments was to determine whether gp120 showed direct neurotoxic effects and/or 
indirect neurotoxic effects and whether fentanyl would act synergistically with gp120. 
Through conducting a Live/Dead Assay, Immunocytochemistry for GFAP/IBA1, and a 
Cytokine Array, it was determined that gp120 shows neither direct nor indirect 
neurotoxic effects, and fentanyl does not exacerbate the effects of gp120. 
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1. Introduction: 
a.     HIV worldwide and in the U.S. 
The human immunodeficiency virus (HIV) epidemic has infected more than 75 
million people worldwide since the first reported cases in 1981, and an estimated 35 
million people have died due to complications associated with HIV (“HIV/AIDS,” 2018). 
Currently, there are approximately 37 million individuals living with the infection (Deeks, 
et al., 2015); roughly 26 million of these individuals live in Sub-Saharan Africa, (Kharsany 
& Karim, 2016) and approximately 1.1 million people live in the United States, 
accounting for an estimated 162,500 who are unaware of their condition (“Drug Use and 
Viral Infections,” 2018). In Sub-Saharan Africa, HIV is most prevalent among women 
aged 15-24 due to cultural interactions (CDC). In the United States, the populations 
most affected by HIV are homosexual African American men and homosexual 
Hispanic/Latino men; both populations have experienced an increase in HIV diagnoses in 
recent years, whereas all other populations have experienced a decrease in diagnoses 
(“Estimated HIV Incidence and Prevalence in the United States,” 2018). 
b.     HIV transmission 
HIV is transmitted from infected individuals through bodily fluids: blood, semen, 
pre-seminal fluid, anogenital fluids, and breast milk. Transmission occurs via viral 
contact with mucus membranes, tissue lesions, or via direct transmission into the blood 
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stream, such as occurs with injection drug use (“HIV/AIDS,” 2018). Individuals 
who inject drugs, hormones, steroids, or silicone can acquire HIV by sharing needles, 
syringes, or other injection equipment due to residual blood from an infected person. 
Additionally, the virus can survive within used injection equipment for up to 42 days, 
depending on environmental conditions (“HIV/AIDS,” 2018). The contribution of 
increased engagement in risky sexual behavior associated with impaired judgment 
associated with drug use is also a consideration (“HIV/AIDS,” 2018). 
c.     HIV effects on the body 
HIV affects all organ systems in the body through its interactions with the 
immune system. HIV targets T cells and reduces cell-mediated immunity which leads to 
severe opportunistic infections and cancers.  HIV infects and eradicates CD4+ T-cells, or 
helper T-cells. CD4+ T-cells mature in the thymus of the human body and aid B cells in 
the production of antibodies, induce macrophage activity, recruit neutrophils, 
eosinophils, and basophils to infection and inflammation sites, and produce cytokines 
and chemokines (Zhu & Paul, 2008). Cytokines and chemokines are secreted, small cell-
signaling protein molecules, whose receptors are expressed on immune cells. These 
factors play a critical role in immune cell differentiation, migration, and polarization into 
functional subtypes and in directing their biological functions (Shachar & Karin, 2013).  
d.     HIV and injecting drug users (IDU) 
While Sub-Saharan Africa contains 70% of the world’s population of HIV positive 
individuals, the main route in that region is heterosexual transmission (Aceijas et al., 
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2004). However, in China, Indonesia, Vietnam, several Asian republics, the Baltic States, 
and North Africa the main route of transmission is primarily unsafe drug-injecting 
practices with additional HIV spread occurring through commercial sex work (Aceijas et 
al., 2004). Additionally, it is estimated that in many countries in Europe, Asia, the Middle 
East, and the Southern Latin America, the sharing of injecting equipment is the primary 
mode of transmission, accounting for 30–90% of all reported infections (Aceijas et al., 
2004). 
In the United States, injection drug use is associated with approximately one-
third of all HIV infections, and approximately 10% of all new HIV diagnoses are 
attributed to injection drug use or male-to-male sexual contact and injection drug 
use (“HIV/AIDS,” 2018). Research has estimated that HIV positive IDU might significantly 
contribute to higher rates of transmission even when compared to those with 
ineffective or inconsistent treatment (Escudero, et al., 2017). 
Even though awareness of transmission of HIV is at an all-time high in the United 
States, the prevalence of illegal opioid drug use also continues to climb. As a result, 
multi-person sharing of needles continues to be a common occurrence. To combat the 
transmission of HIV and other diseases through infected needles, the United States 
established the Syringe Service Programs (SSPs). SSPs allow individuals to exchange used 
syringes for sterile syringes; this has shown to decrease the spread of HIV, while not 
increasing the prevalence of illegal drug use (“Syringe Services Programs,” 
2018).  Additionally, even with the establishment of a treatment protocol for HIV, called 
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cART, HIV positive individuals with transmission via IDU continue to experience shorter 
lifespans (Marcus, et al., 2016). 
e.     Opioid toxicity 
The most commonly injected drugs are opioids; the most abused opioid is heroin 
(Baciewicz, 2012). Chronic opioid use leads to multiple impairments in the central 
nervous system: increased microglial activation, increased axonal damage, increased 
neuronal loss, increased vasculopathy, and decreased astrocytes. Additionally, chronic 
opioid use has been shown to cause dizziness, sedation, hyperalgesia associated with 
increased sensitivity to pain, and increased rates of clinical depression and other mental 
illnesses (Arts & Hazuda, 2012).  
f.      Opioids and HIV 
While the mechanisms in which opioids contribute to the increased 
neurocognitive impairments are not completely understood, the regulation of immune 
cell functions is thought to play a role (Jaureguiberry-Bravo, et al., 2018). Studies have 
shown that opiate abuse may act at multiple glial-cell types to further compromise 
neuron function and survival (Hauser, et al., 2012). Opioids also allow easier access to 
HIV to enter the brain by weakening the blood brain barrier (BBB) and cause greater 
nerve cell injury (“Opioid Overdose Death Rates,” 2018). Additionally, opioids potentiate 
the effects of HIV by promoting the progression to Acquired Immunodeficiency 
Syndrome (AIDS), increasing the frequency and severity of HIV encephalitis, and 
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potentiating the symptoms of HIV Associated Neurocognitive Disorder (HAND) 
(Jaureguiberry-Bravo, et al., 2018). 
g.     The effects of fentanyl 
From 2002-2017, there was a 4.1-fold increase in the total number of opioid 
overdose related deaths and a 900% increase in the number of individual seeking 
treatment for prescription opioid abuse (Kolodny A, et al., 2015). In 2016 alone, more 
than 42,000 individuals in the U.S. died from opioid overdoses – more than 115 per day 
– and synthetic opioids were involved in approximately 50% of overdoses (“Opioid 
Overdose Death Rates,” 2018). The most commonly used synthetic opioid was fentanyl; 
from 2002-2017, there was a 22-fold increase in the total number of deaths due to 
fentanyl (“Fentanyl and Other Synthetic Opioids Drug Overdose Deaths,” 2018). 
Fentanyl is approximately 50 times more potent than heroin and 100 times more potent 
than morphine and negates naloxone, an opioid antagonist that reverses and blocks the 
effects of opioids (“Opioid Overdose,” 2016). It is because of these reasons that fentanyl 
is driving the opioid epidemic. 
h.     HIV patients and pain 
Due to the neuropathic properties of HIV, over 50% of HIV patients suffer from 
chronic pain and are often prescribed opioids to combat the pain (Liu, Bolong et al., 
2016). Studies show that opioids exacerbate the negative effects of HIV on the nervous 
system by promoting damage of the neurons, activation of caspase dependent and 
independent pro-apoptotic pathways, and disruption of glial functions; opioids can also 
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activate glial cells, such as microglia and astrocytes (Liu, Bolong et al.,2016). The 
activation of glial cells may facilitate the expression of hyperalgesia by releasing 
cytokines, chemokines, and brain-derived neurotrophic factor (Liu, Bolong et al., 2016).  
i.      NeuroAIDS 
Drug abuse and HIV are interlinked epidemics; individuals who are HIV positive 
and abuse drugs show more severe symptoms of neurocognitive impairments linked to 
HIV, sometimes collectively referred to as “NeuroAIDS.”  Since the development of 
combined antiretroviral therapy (cART) in 1996, the number of deaths due to HIV has 
decreased and individuals are able to live longer with the infection (Saylor, et al., 2016). 
cART aids in counteracting progression of HIV in the peripheral nervous system but 
cannot accumulate in the central nervous system due to its inability to permeate the 
blood brain barrier (Kumar, et al., 2018). Due to the increase of life expectancy, HIV-
infected patients now contend with more neurocognitive impairments: mood disorders, 
cognitive impairment, behavioral disinhibition, motor impairment, and peripheral 
neuropathies associated with HIV patients (Saylor, et al., 2016). These neurocognitive 
impairments, which affect approximately 50% of all HIV patients, have been deemed as 
HIV Associated Neurocognitive Disorder (HAND) (Arts & Hazuda, 2012). Three categories 
of HAND have been discovered by researchers: Asymptomatic Neurocognitive 
Impairment (ANI), Mild Neurocognitive Disorder (MND), and HIV Associated Dementia 
(HAD) (Arts & Hazuda, 2012). Individuals who suffer from ANI show no impairment in 
activities of daily living (Arts & Hazuda, 2012) but show HIV associated cognitive 
impairment of at least two cognitive areas, such as memory, processing speed, 
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attention, sensory perceptual and motor skills (Kumar, et al., 2018). Individuals who 
suffer from MND show impairment in activities of daily living (Arts & Hazuda, 2012) with 
a decline in brain function, movement skills, and shifts in behavior (Kumar, et al., 2018). 
Individuals who suffer from HAD show marked impairment in activities of daily living 
and include individuals who suffer from HIV associated dementia and HIV-encephalitis, a 
neuro-inflammatory condition characterized by the presence of activated and infected 
microglia, multinucleated giant cells, astrogliosis, and loss of myelin (Saylor, et al., 
2016). cART has successfully decreased the severity of HAND, but not the prevalence; 
the majority of individuals that are HIV positive now live with HAND but suffer from the 
less severe types (Saylor, et al., 2016). Additionally, HIV positive individuals with 
transmission via IDU have shorter lifespans even with the addition of cART (Festa & 
Meucci, 2012). 
j.      HIV envelope protein gp120 and its effect on NeuroAIDS 
The HIV protein gp120 is a highly glycosylated envelope protein that assists with 
viral entry into the cell through a conformational change in CD4 and a g-protein coupled 
receptor (GPCR) (Rich et al., 2019). While CD4 is necessary for viral entry, it is not 
sufficient, and HIV requires an additional interaction with GPCR chemokine co-
receptors. Through the binding of viral glycoproteins and cell surface glycoproteins the 
process of adsorptive endocytosis begins. Broadly, HIV often parsed into three primary 
strains X4, R5, and a dual X4 and R5 strain, albeit, additional strains exist, particularly in 
world regions with poor virulence control. These strains are determined by the 
selectivity of the gp120 molecule for a particular co-receptor, called a “tropism” (Rich et 
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al., 2019). In X4-tropic strains, gp120 is associated with the CXCR4 chemokine receptor, 
and in R5-tropic strains, gp120 is associated with the CCR5 chemokine receptor (Rich et 
al., 2019). The CXCR4 co-receptor is the C-X-C motif chemokine receptor 4 and is one of 
the chemokine receptors expressed primarily on T-cells (Charo et al., 2018).  In the 
periphery, CXCR4 plays a role in cell migration and acts as a receptor for extracellular 
ubiquitin by increasing intracellular calcium ion levels (“C-X-C Chemokine Receptor Type 
4,” 2018). The CCR5 co-receptor is the C-C motif chemokine receptor 5 and is one of the 
chemokine receptors expressed on multiple cell types, including macrophages and some 
types of T-cells (Woollard & Kanmogne, 2015). R5 strains predominate in early stages of 
HIV infection, and X4 strains emerge in later stages (Woollard & Kanmogne, 2015).  
Gp120 has been shown to have a wide variety of neurotoxic effects on the CNS. 
Gp120 increases cell death of astrocytes through stress-mediated apoptosis (Shah et al., 
2012). Additionally, gp120 alters the BBB by increasing the permeability; the BBB aids in 
proper functioning and homeostasis of the CNS by regulating the trafficking of 
molecules (Shah, Ankit et al.). Gp120 increases the expression of proinflammatory 
cytokines and chemokines which promotes leukocyte chemotaxis to inflammation sites 
(Charo et al., 2018). Although the mechanisms are not fully understood, gp120 enlarges 
and damages mitochondria and impairs the transport of mitochondria along 
microtubules (Avdoshina et al., 2016). Gp120 also inhibits microtubule polymerization 
and tubulin acetylation, which results in impaired axonal function (Avdoshina et al., 
2017). These findings suggest that the mechanism of gp120 neurotoxicity is contributed 
to the detrimental effects on microtubules. 
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k.     Hypothesis 
To determine if gp120 was directly neurotoxic, we exposed differentiated human 
neuroblastoma cells to X4-gp120 and/or R5-gp120 (10 – 1000 pM).  To assess the extent 
to which gp120 exerted indirect toxicity via neuroinflammation, in the absence or 
presence of an abused opioid, primary mixed glia were obtained from mice and exposed 
to X4- or R5 gp120 (500 pM) with or without co-exposure to fentanyl. We hypothesized 
that gp120 would show both direct and indirect neurotoxic effects and fentanyl would 
potentiate these effects. 
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2.     Methods 
2.1 Description of Cells and Cell Culture Processes 
a.  SH-SY5Y human neuroblastoma cells 
An SH-SY5Y cell line was received from the American Type Culture 
Collection (ATCC; Manassas, VA). Cells were relocated from growth flasks into 24 
well plates and allowed to grow in media (DMEM/F12 89.5%, Fetal Bovine Serum 
10%, Antibiotic (PSF) 0.5%) in an incubator kept at 37°C and 5% CO2. Once the 
cells were at 50% confluency, Retinoic Acid (50 mG retinoic acid, 33.3 mL 95% 
EtOH) was added to begin differentiation. After ~6 days, BDNF (10 µG BDNF, 1 
mL DMEM/F12) was added to continue differentiation. Throughout the 
differentiation process, a full media exchange occurred every 48 hours and 
plates were kept in an incubator (Paris et al., 2019).  
b. Primary mouse mixed glia cells 
Primary mixed glial cultures were prepared as previously described (Paris 
et al., 2016). Briefly, mixed-glia were obtained from the whole-brain postnatal 
day 0–1 C57BL/6HNsd. Brains were minced before being incubated (37˚C, 5% 
CO2) with trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Life Technologies, Carlsbad, CA) for 30 min. Tissues 
were triturated and sequentially filtered through 100-µm and 40-µm diameter 
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pore cell strainers (Greiner Bio-One, Kremsmünster, Austria). Cells were 
plated at a density of 150,000 cells/well onto poly-L-lysine-coated (Sigma–
Aldrich, St. Louis, MO) 24-well culture plates and maintained for 11-14 days in 
DMEM supplemented with 10% fetal bovine serum (Thermo Scientific Hyclone, 
Logan, UT). The mixed glial cells were harvested from 0-2 day old C57 BL/6HNsd 
pups and were seeded on 24- well plates at a density of 150,000 per well (Paris 
et al., 2016). 
2.2 Experimental Procedures 
a. Live/Dead Assay 
After the SH-SY5Y cells were grown to 80% confluency and seeded onto a 
24-well plate at a density of 50,000 cell/well, gp120 X4 and gp120 R5 received 
from ImmunoDX (Woburn, MA) were used to treat the cells. X4-gp120 and/or 
R5-gp120 were used at concentrations of 0, 10, 100, and 1000 pM. Fluorescents 
were added to the wells by mixing the fluorescents with the gp120 treatments or 
media per the controls. A master mix of propidium iodide/DAPI was created with 
gp120 media (one drop of propidium iodide/DAPI was added per mL of gp120 
treatments/media) at time 0 and the number of red positive cells were counted 
at 0, 24, and 48 hours, but the cell death reached over 60% at 48 and no group 
differences were observed as such and only hours 0-24 were used for analyses. 
Propidium iodide is a membrane impermeable dye that only stains the DNA of a 
cell if the membrane is compromised. DAPI is a membrane permeable dye that 
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stains the DNA in all cells. By comparing those that were propidium iodide 
stained and the total number of cells, the percent of dead cells was determined.  
b.  Immunocytochemistry for GFAP/IBA1 
Wells were treated with gp120 X4 or gp120 R5 at a concentration of 500 
pM, as well as fentanyl was obtained from: Sigma Aldrich (St. Louis, MO; #F-013) 
diluted to final concentration in media at 1 µM. 24 hours later, cells were fixed in 
4% Paraformaldehyde. Permeability solution (0.1% Triton X 100, 0.1% Bovine 
Serum Albumin in PBS) was added to each well and incubated at room 
temperature for 30 minutes. Then the permeability solution was removed and 
blocking solution (1% Bovine Serum Albumin, 1% Normal Goat Serum in PBS) was 
added to each well and incubated at room temperature for 30 minutes. Blocking 
solution was removed and primary antibodies, (Wako (Richmond, VA) anti-Iba 1 
Milipore (anti-gfap) mab360 Burlington, MA 1:250 dilution in Blocking Solution) 
were added to each well and incubated overnight in a 4°C moisture chamber. 
The next day, the primary antibodies were removed, and the wells were washed 
with PBS 3 times for 10 minutes each. Secondary antibodies (Alexafluor 594 and 
488 (Carlsbad, CA) 1:500 dilution in Blocking Solution) were added to the wells 
and incubated in the dark for one hour at room temperature. After an hour, the 
secondary antibodies were removed, and the wells were washed with PBS 3 
times for 10 minutes each. Hoechst 33342 (1:10,000 dilution in PBS) was added 
to each well and incubated at room temperature in the dark for 8 minutes. The 
Hoechst was removed, and the wells were washed with PBS 3 times for 10 mins 
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each. The plates were kept in the dark until ready to be imaged by a Nikon Ti2 
microscope. By using Image J software, the number of microglia were counted 
and integrated density of astroglia was calculated. Microglia were counted by 
selecting a random field with at least 200 cells per field and determining the 
number Hoechst positive cells and the number of Iba-1 positive cells. To 
determine the integrated density of astroglia, the images were uploaded to 
ImageJ and a threshold was developed to distinguish signal from the 
background. From the signal, Image J software was able to determine the 
intensity and the area. Integrated density was determined by calculating the 
mean intensity of signal multiplied by the total area of signal.  
c.     Cytokine array 
Proteome Profiler Antibody Array: Mouse Cytokine Array Panel A ary-006 
was purchased from R&D Systems, Inc. Minneapolis, MN and the array protocol 
for cell culture supernatants was performed according to manufacturing 
recommendations. To determine levels of mouse chemokines and cytokines, cell 
culture supernatants were placed on pre-coated membranes to determine the 
level of cytokine activity in cell supernatants for 38 cytokines. These cytokines 
included pro-inflammatory cytokines (TNFa, IFNg, IL-1a, IL-1b, IL-2, IL-3, IL-6, IL-7, 
IL-12p70, IL-16, IL-17, IL-23, and IL-27), anti-inflammatory cytokines (IL-1ra, IL-4, 
IL-5, IL-10, and IL-13), and chemotactic/regulatory cytokines (C5, G-CSF, GM-CSF, 
TIMP-1, TREM-1, CD54, CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL12, CCL17, 
 14 
CXCL1, CXCL2, CXCL9, CXCL10, CXCL11, and CXCL13). Images of the membranes 
were taken, and level of intensity was determined on a LI-COR imager.  
d. Statistical analyses 
Dependent measures for Live/Dead analyses were via separate, one-way 
Repeated Measures ANOVAs with gRp120 concentration as the between-
subjects factor (0, 10, 100, and 1000 pM) and time as the within-subjects factor 
(0 or 24 h post-treatment). Dependent measures for immunocytochemical 
endpoints were assessed via separate, two-way ANOVAs with gp120 condition 
(control, X4, or R5) and fentanyl condition (vehicle or fentanyl) as between-
subjects factors. Fisher’s Protected Least Significant Difference post hoc tests 
determined group differences following main effects. Interactions were 
delineated via simple main effects and main effect contrasts with alpha 
controlled for multiple comparisons. Analyses were considered significant when 
p < 0.05. 
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3. Results 
3.1 Live/Dead Assay 
To determine if direct neurotoxicity was present, SH-SY5Y human 
neuroblastoma cells treated with X4-gp120 and or R5-gp120 (0, 10, 100, or 1000 
pM) were maintained in media containing DAPI and propidium iodide and 
imaged at 0, 24, and 48 hours. After 48 hours, there were no group difference 
between percent cell death (data not shown). There was a significant interaction 
[F(3,4)=3.59, p<.05)] from 0 to 24 hours such that X4-gp120 decreased cell death 
at 10 pM (Fig. 1A). Although cell death increased from 0 to 24 hours, there was 
no significant interaction between treatment conditions of R5-gp120 (Fig. 1B) 
and X4/R5-gp120 (Fig. 1C) (0, 10, 100, or 1000 pM) from 0 to 24 hours. 
3.2 Immunocytochemistry for GFAP/IBA1 
To determine if indirect neurotoxicity was present and if fentanyl 
exacerbated the effect, primary mouse mixed glial cells were treated with X4-
gp120 or R5-gp120 (500 pM) with and without the presence of fentanyl. 
Although a decrease in frequency for microgliosis (Fig. 2A) and integrated 
density for astrogliosis (Fig. 2B) were both present, there was no significant 
interaction within groups. 
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3.3 Cytokine Array 
To determine if neurotoxicity was present and if fentanyl exacerbates the 
effect through the influence of cytokines or chemokines, cell supernatant from 
the primary mouse mixed glial cells that were treated with X4-gp120 or R5-
gp120 with and without the presence of fentanyl were taken and used on a 
cytokine/chemokine array. Although fentanyl caused an increase of the 
chemokines CXCL10 and CCL2 (Fig. 3A), the data did not reach significance. 
Additionally, there were no significant interactions concerning any cytokines 
(Fig. 3B) or individual interactions with either X4-gp120 or R5-gp120 (Fig. 3A/B).  
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4.     Discussion 
The expectations of these experiments were that gp120 would show both direct 
and indirect neurotoxic effects through increasing cell death, astrogliosis, microgliosis, 
and the presence of cytokines and chemokines. Additionally, it was expected that 
fentanyl would act synergistically with gp120 and exacerbate the effects. The live/dead 
assay showed a significant decrease in cell death of X4-gp120 at 10 pM from 0 to 24 
hours; however, all other data were not significant. Due to the lack of direct 
neurotoxicity, indirect neurotoxicity was expected to occur through astrogliosis and 
microgliosis. Immunocytochemistry for GFAP and IBA1 did not 
reveal significant differences, but there was an apparent effect. To assess whether 
innate immune modulators were influenced, a cytokine array was performed. Fentanyl 
had an apparent effect with the chemokines CXCL10 and CCL2, but these data were 
exploratory (n=2/group) and groups did not significantly differ. Although the findings 
were intriguing, they did not reach significance and the original hypothesis 
was rejected.  
            Previous literature has proposed direct neurotoxicity to neurons through gp120 
initiating the release of a glutamatergic excitotoxin from infected microglia and 
macrophages (Howard et al., 1999). The agent reacts with NMDA receptor and calcium-
dependent excitotoxic damage to neurons through calcium mobilization (Howard et al., 
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1999). Calcium mobilization causes a downstream reaction in which the generation of 
reactive oxygen species (ROS) and lipid peroxidation occur (Howard et al., 1999). The 
exact mechanism in which the gp120 mobilized calcium causes accumulation of ROS is 
unknown; however, accumulation has been shown to occur in both neurons and glia 
(Howard et al., 1999). Accumulation of ROS in neurons is consistent with the proposal of 
gp120 activating NMDA-dependent pathways, whereas ROS in glia indicate that gp120 
mobilizes cytosolic calcium within astrocytes (Howard et al., 1999). 
Additionally, gp120 has been shown to have direct neurotoxic affect through 
alterations in mitochondrial fusion/fission and mitochondria biogenesis (Fields et al., 
2016). Mitochondrial fusion is dependent on MFN1, MFN2, and OPA1; mitochondrial 
fusion is dependent on DRP1 (Fields, et al.). Experiments have shown levels of MFN1, 
OPA1, and DRP1 were altered in the brains of HAND patients and in gp120 transgenic 
mice (Fields et al., 2016). Additionally, gp120 transgenic mice showed damaged 
mitochondria and increased markers of neuroinflammation (Fields et al., 2016). 
Furthermore, the G protein coupled receptor CXCR4 and its endogenous ligand 
CXCL12 have been shown to play a role in neuronal proliferation, maturation, survival, 
and the regulation of dendritic spine density (Festa & Meucci, 2012). Both CXCR4 and 
CXCL12 are constituently expressed in the human brain and CXCL12 has been shown to 
dictate neuronal survival, neuronal transmission, and alter excitotoxic pathways (Festa 
& Meucci, 2012). Disrupting the connection between CXCR4 and CXCL12 has negative 
impacts within the brain. Through the cleavage of CXCL12, the neuroprotective function 
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of CXCR4 is impaired and an alternate receptor, CXCR3, is activated and causes neuronal 
injury (Festa & Meucci, 2012). 
As gp120 binds to CXCR4, MAP kinases are activated and CXCR4 internalization 
and dimerization is induced (Festa & Meucci, 2012). Gp120 then induces pathways 
associated with apoptosis, such as p38 and caspase-3, even in the absence of glia and 
CXCR4 internalization (Festa & Meucci, 2012). Additionally, gp120 has been shown to 
directly interact with neurons through experimentation that proved CXCL12, CXCR4 
inhibitors, and Gi-signaling inhibitors all reduced or blocked gp120-induced 
neurotoxicity (Festa & Meucci, 2012). 
Although these experiments did not match what was seen in previous literature, 
several features could have played a factor. For example, receiving gp120 from different 
manufacturers could have resulted in different results due to different amounts of 
glycosylation. After using the enzyme PNGase F to deglycosylate gp120, our lab has 
observed toxicity increased between 6-10% in a concentration-dependent manner. 
Additionally, the present experiment used SH-SY5Y cells that were differentiated in 
BDNF which may have been protective. Assessing different cell types could show 
different direct toxicity profiles as well as potential regional vulnerability via the 
assessment of primary cells from selected brain regions as opposed to those obtained 
from the whole brain as was done herein. As well, In lieu of time-lapse microscopy, 
propidium iodide was added at T0; due to unexpected toxic properties of propidium 
iodide, it caused an increase in cell death which may have masked our capacity to 
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see effects. In future experiments, the use of time-lapse microscopy or an end point 
analysis where cell death is measured at 24 or 48 would be beneficial. Lastly, cytokine 
arrays were informative, but revealed targets that were semi-quantitative; more 
observations are needed, and future studies will replicate the work and employ an ELISA 
on targets of interest, CCL2 and CXCL10.  
Future avenues of research include determining the relationship of other HIV 
proteins, such as Tat and Vpr, that contribute to neurotoxicity and opioids. Tat, or the 
transactivator of transcription, has been linked to progressive neuronal deregulation 
that leads to the development of HAND and accelerated brain aging (Bagashev & Bassel, 
2013). Tat increases the expression of chemokine receptors, induces cytokine release, 
induces oxidative stress, attracts monocytes, and promotes immune cell permeation 
across the BBB (McRae, 2016). Vpr plays an important role in the rate of viral replication 
and the effects of the viral on T cells; however, the most detrimental characteristic of 
Vpr is that it allows the replication of HIV within macrophages (Gonzalez, 2017). 
While women account for 52% of all HIV infections worldwide and women aged 
10-24 are twice as likely as men the same age to acquire an HIV infection (CDC), men are 
more likely to die due to an HIV infection (Maskew, et al., 2013). Women typically 
represent a higher CD4 count when compared to men while participating in cART 
(Maskew, et al., 2013). CD4 count is strongly associated with mortality in HIV patients; 
individuals with higher CD4 counts are less like to die (Lawn et al., 2008). While women 
are more susceptible to acquiring an HIV infection, there is higher immune activation in 
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women than men and women are less likely to progress as quickly to NeuroAIDS when 
compared with men (Griesbeck et al., 2016) 
One of the hypotheses as to why women are less likely to progress to NeuroAIDS 
as quickly is the presence of female hormones. Recent studies have shown that both 
progesterone and allopregnanolone (AlloP) show neuroprotection when administered 
to animals with acute brain injury (Paris, et al., 2016). Researchers hypothesize that 
progesterone and AlloP protect neurons by suppressing the inflammatory 
response (Paris, et al., 2016). While progesterone and AlloP show protection, neither 
show evidence of enhanced proliferation or migration (Paris, et al., 2016). 
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Figure 1A: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM 
of X4-gp120 from 0 to 24 hours. There was a significant interaction [F(3,4)=3.59, p<.05)] 
from 0 to 24 hours such that X4-gp120 decreased cell death at 10 pM.  
 
Figure 1B: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM 
of R5-gp120 from 0 to 24 hours. There were no significant interactions between 
treatment conditions.  
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Figure 1C: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM 
of X4/R5-gp120 from 0 to 24 hours. There were no significant interactions between 
treatment conditions.  
 
Figure 1D: Image of SH-SY5Y cell line stained with cell-permanent Hoechst and cell-
impermanent Propidium Iodide stains.  
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Figure 2A: Frequency of microglia was determined by selecting a random field 
containing at least 200 cells and counting the number of Hoechst positive cells and Iba-1 
positive cells. Although a decrease in frequency was present, there was no significant 
interaction within groups. 
 
Figure 2B: Image of microglia (20X) stained with Ionized Calcium Binding Adaptor 
Molecule 1 (Iba-1) and the nucleus of the cell was stained with Hoechst.  
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Figure 2C: Integrated density of astroglia determined through ImageJ software by 
calculating the mean intensity of signal multiplied by the total area of signal. Although a 
decrease in integrated density was present, there was no significant interaction within 
groups. 
 
Figure 2D: Image of astrocytes (40X) stained with Glial Fibrillary Acidic Protein and 
nucleus of the cell stained with Hoechst. Images were used to develop a threshold that 
would distinguish signal from the background. From the signal, Image J software was 
able to determine the intensity and the area. 
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Figure 3A: Cytokine activity was determined by measuring the levels of fluorescent units 
from the mixed glial cell supernatant on a cytokine array panel.  
 
Figure 3B: Chemokine activity was determined by measuring the levels of fluorescent 
units from the mixed glial cell supernatant on a cytokine array panel.  
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Figure 3C: Cytokine Array Panels determine the level of mouse chemokines and 
cytokines produced by mixed glial cells. Intensity levels were determined by a LI-COR 
software.  
